Understand the source comparison
NAD+ Mitochondrial Health Results Timeline: Comparison
Days 1–7 NAD+ pool replenishment, SIRT1 activation begins 20–40% increase in intracellular NAD+ (measurable via HPLC) None to minimal. Placebo-driven perception possible True cellular engagement, no functional output yet. This is expected Days 7–14 SIRT1 deace
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Days 1–7
- NAD+ pool replenishment, SIRT1 activation begins
- 20–40% increase in intracellular NAD+ (measurable via HPLC)
- None to minimal. Placebo-driven perception possible
- True cellular engagement, no functional output yet. This is expected
- Days 7–14
- SIRT1 deacetylates PGC-1α, mitochondrial biogenesis signaling initiated
- PGC-1α mRNA expression up 30–50%, no mitochondrial density change yet
- Slight reduction in afternoon energy crashes reported anecdotally
- Gene expression shifts confirmed. Protein synthesis lag means no ATP capacity increase
- Weeks 2–4
- Mitochondrial DNA replication, new mitochondrial protein synthesis
- mtDNA copy number increase detectable, OXPHOS complex protein levels rising
- Energy stabilization, reduced reliance on stimulants, improved sleep quality
- First phase where subjective reports align with measurable mitochondrial capacity gains
- Weeks 4–6
- Mitochondrial density increase, ATP synthesis capacity rises
- 15–25% increase in mitochondrial respiration (measured via Seahorse assay)
- Sustained physical output improvement, faster exercise recovery
- This is the verification window. Improvements here confirm mitochondrial biogenesis
- Weeks 8–12
- Chronic sirtuin activity, oxidative stress defense upregulation, metabolic adaptation
- Reduced ROS production, improved NAD+/NADH ratio, stable mitochondrial membrane potential
- Plateau of subjective benefits, maintenance phase begins
- Full metabolic adaptation. Further gains require protocol adjustment or combination strategies
- Week 12+
- Maintenance of elevated NAD+ pool, sirtuin pathway sustained
- Stable biomarker levels, no further acute gains without dose/protocol change
- Benefits persist but do not amplify. Regression begins 2–4 weeks post-cessation
- This is the long-term maintenance phase. Discontinuation reverses gains within 4–6 weeks